Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

Diabetes, Obesity and Metabolism

Volumn 20, Issue 4, 2018, Pages 889-897

  Vilsbøll, Tina ^a   Bain, Stephen C ^b   Leiter, Lawrence A ^c   Lingvay, Ildiko ^d   Matthews, David ^e   Simó, Rafael ^f   Helmark, Ida Carøe ^g   Wijayasinghe, Nelun ^g   Larsen, Michael ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g NOVO NORDISK A S   (Denmark)

Author keywords

antidiabetic drug; diabetic retinopathy; GLP 1 analogue

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; PLACEBO; SEMAGLUTIDE; GLUCAGON LIKE PEPTIDE;

ARTICLE; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; JAPANESE (PEOPLE); NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT IDENTIFICATION; POST HOC ANALYSIS; RISK ASSESSMENT; ADULT; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; JAPAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; GLUCAGON-LIKE PEPTIDES; GLYCATED HEMOGLOBIN A; HUMANS; JAPAN; MALE; MIDDLE AGED; RISK FACTORS;

EID: 85041694897     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13172     Document Type: Article

References (27)

1. Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015;55(5):497-504.
2. Marbury TC, Flint A, Jacobsen JB, Derving Karsbol J, Lasseter K. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment. Clin Pharmacokinet. 2017;56(11):1381-1390.
3. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251-260.
4. Ahren B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341-354.
5. Ahmann A, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide vs. exenatide ER in subjects with type 2 diabetes (SUSTAIN 3). American Diabetes Association, 76th Annual Scientific Sessions; June 10-14, 2016: New Orleans, LA.
6. Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355-366.
7. Rodbard HW, Lingvay I, Reed J, et al. Efficacy and safety of semaglutide once-weekly vs placebo as add-on to basal insulin alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN 5). European Association for the Study of Diabetes, 52nd Annual Meeting; September 12-16, 2016: Munich, Germany.
8. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844.
9. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-564.
10. ACCORDION Eye Study Group, ACCORDION Study Group. Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the action to control cardiovascular risk in diabetes (ACCORD) follow-on study. Diabetes Care. 2016;39(7):1089-1100.
11. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
12. Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
13. Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116(7):874-886.
14. American Diabetes Association. Standards of medical care in diabetes-2016 abridged for primary care providers. Clin Diabetes. 2016;34(1):3.
15. American Diabetes Association. Management of diabetes in pregnancy. Diabetes Care. 2015;38(suppl):S77-S79.
16. Gorman DM, le Roux CW, Docherty NG. The effect of bariatric surgery on diabetic retinopathy: good, bad, or both? Diabetes Metab J. 2016;40(5):354-364.
17. Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial. N Engl J Med. 1984;311(6):365-372.
18. Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T. Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes. 1985;34(suppl 3):74-79.
19. Dahl-Jørgensen K. Near-normoglycemia and late diabetic complications. The Oslo Study. Acta Endocrinol Suppl. 1987;284:1-38.
20. Sanofi-Aventis. Lantus® (insulin glargine), EU summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000284/WC500036082.pdf. Accessed May 31, 2017.
21. Davis MD, Beck RW, Home PD, Sandow J, Ferris FL. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin. Exp Clin Endocrinol Diabetes. 2007;115(4):240-243.
22. Rosenstock J, Fonseca V, McGill JB, et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia. 2009;52(9):1778-1788.
23. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.
24. Varadhan L, Humphreys T, Hariman C, Walker AB, Varughese GI. GLP-1 agonist treatment: implications for diabetic retinopathy screening. Diabetes Res Clin Pract. 2011;94(3):e68-e71.
25. Varadhan L, Humphreys T, Walker AB, Varughese GI. The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy. Diabetes Res Clin Pract. 2014;103(3):e37-e39.
26. US Food & Drug Administration Medical Reviews. Albiglutide. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125431Orig1s000MedR.pdf. Accessed May 31, 2017.
27. Novo Nordisk. Data on file. 2017.